

Fellowship in Industry Program

2024





About University of the Pacific

University of the Pacific is a nationally ranked university with a long tradition of dedicated teaching, small class sizes, practical experience and vibrant residential life. The breathtaking main campus in Stockton, California is home to six schools and colleges, with more than 100 majors and programs of study. The Thomas J. Long School of Pharmacy opened in 1955 and has a long-standing record for producing high-quality pharmacists with the option for dual degree programs (PharmD/PhD or PharmD/MS) and post-doctoral academic fellowships. Over the last nine years, average annual faculty research grants in the School totaled more than one million dollars with extensive participation in NIH and NSF grants and more than 95 percent of faculty publishing. The School touts a unique decentralized Advanced Pharmacy Practice Experience (APPE) model with seventeen regions having faculty members bolstering teaching, scholarship and service.

Learn more at pacific.edu/pharmacy

Mission

The mission of the Thomas J. Long School of Pharmacy is to prepare students for lifelong success in health careers by providing an excellent, student-centered learning environment. We aspire to develop leadership skills in our students and a strong commitment to their professions, to interprofessional collaboration, and to society. These efforts are assisted by linkages across the University of the Pacific professional and liberal arts programs. We support outstanding professional and graduate teaching, research and other scholarly activity, and services as a means of achieving our mission.

Welcome message from the Associate Dean of Professional Programs



Dear Prospective Fellow,

We are so pleased that you are considering the University of the Pacific's Fellowship in Industry Program (FIP) in partnership with BeiGene. The goal of this program is to increase industry fellowship opportunities offered through partnerships between biopharmaceutical organizations and universities.

At University of the Pacific, the first charter university in California, we value individualized training and focus on leadership development, which are exemplified by our partnership with BeiGene. For more than 60 years, the Thomas J. Long School of Pharmacy has been training health care professionals who are problem-solvers, innovators and leaders. Our faculty dives deeper, using research to challenge the status quo of health care and education.

As an FIP fellow, you will be fully immersed in a Clinical Development role at BeiGene supporting innovative drug development. In addition, you will have opportunities to work alongside the faculty and preceptors at the University, Veteran Affairs Palo Alto Health Care System and Travis region where you can engage in research collaboration, grant and manuscript development, teaching, student and resident mentoring and other professional development activities.

I highly encourage you to contact our FIP Director, Dr. Sachin Shah, and the exceptional team of program mentors so you can appreciate how this program can further your future success.

Best regards,

Allen Shek, PharmD

Professor of Pharmacy Practice
Associate Dean of Professional Programs
Thomas J. Long School of Pharmacy
University of the Pacific

UNIVERSITY OF THE
PACIFIC

Thomas J. Long
School of Pharmacy

About BeiGene

At BeiGene, our mission is to build the first next-generation global biotechnology company – one that expands the highest quality therapies to more people around the world – by addressing the two biggest challenges in fighting cancer today: access to medicines and affordability.

We are a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide. We currently have three approved medicines that were discovered and developed in our own labs, including BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. We have obtained approvals to market BRUKINSA in the United States, China, EU, the UK, Canada, Australia and additional international markets, and TEVIMBRA in United States, China and EU. Additionally, the U.S. Food and Drug Administration has accepted for review a Biologics License Application for TEVIMBRA.

BeiGene's oncology-focused research team, with more than 1,100 scientists, is one of the largest in the industry and continually seeks to accelerate the rate at which we discover innovative medicines for patients with the highest unmet needs. Additionally, our global clinical development team, with more than 2,600 colleagues, is fueling this innovation through its passion and commitment to developing new therapies. With our unique business model, we draw from the best science, talent, and collaborative minds around the world to achieve our mission.

Learn more at [BeiGene.com](https://www.bei.com)

Values

- Patients First.** Stand up for more affordable medicines for patients everywhere and improve global health and well-being.
- Bold Ingenuity.** Challenge the status quo to deliver science once thought to be impossible and make bold commitments and deliver against them.
- Collaborative Spirit.** Foster superior, non-hierarchical teamwork and respect individual differences.
- Driving Excellence.** Make a lasting impact in the world and have a sense of urgency and agility to follow the science and deliver for patients while maintaining integrity.

10,000+ employees

45+

To date, we have planned trials or enrolled patients in more than 45 countries

20+

Clinical candidates in pipeline

70+

Markets with regulatory approval for three internally developed medicines

22,000+

Patients¹ enrolled in clinical trials with BeiGene assets to date

1M+


Over one million patients treated with BRUKINSA and TEVIMBRA to date

20,000+

Volunteer hours logged by colleagues globally

¹ Number of patients includes those Investigator Initiated Trials (ITs)

Productive Research and Path to Global Oncology Leadership



*Approved 2019-2021

SM, Small Molecule; mAb, Monoclonal Antibody; ADC, Antibody Drug Conjugate; TAA, Tumor Associated Antigen; CDAC, Chimeric Degradation Activating Compound (targeted protein degradation); BsAb, Bispecific Antibody; TsAb, Trispecific Antibody; CAR-NK, Chimeric Antigen Receptor-Natural Killer Cell

Innovations from Our Pipeline

Our deep portfolio is currently built around two foundational assets, BRUKINSA (zanubrutinib) and TEVIMBRA, developed as a centerpiece and building block for multiple potential combinations. Beyond these medicines, we have around 50 molecules in clinical development and the commercialization phase that leverage a wide array of modalities across multiple indications.



- BTK¹ inhibitor, approved in more than 60 countries and regions, including the U.S., EU, and China, and being developed globally
- Unique pharmacologic properties designed to maximize BTK occupancy and minimize off-target binding compared to other BTK inhibitors
- Indications: CLL; mantle cell lymphoma (MCL); small lymphocytic lymphoma (SLL); Waldenstrom macroglobulinemia (WM); marginal zone lymphoma (MZL)
- Indications in development: lupus nephritis (LN); follicular lymphoma (FL); diffuse large B-cell lymphoma (DLBCL)



- Anti-PD-1² monoclonal antibody, approved in China and EU and being developed globally
- Differentiated mechanism minimizes binding to FcγR, attractive binding epitope
- Indications: lung, liver, gastric, and esophageal cancers; classical Hodgkin's lymphoma; urothelial carcinoma; nasopharyngeal cancer; microsatellite instability-high (MSI-High) cancer

PARTUVIX™ (PARP)

- Small molecule inhibitor of PARP1³ and PARP2, approved in China
- Pharmacological properties such as brain penetration and PARP-DNA complex trapping in preclinical models
- Indications: ovarian and gastric

Ociperlimab (TIGIT)

- An investigational anti-TIGIT⁴ monoclonal antibody
- One of the most advanced anti-TIGIT antibodies in clinical development, highly potent with intact Fc function
- Indications: cervical cancer; non-small cell lung cancer; esophageal squamous cell carcinoma; locally advanced and metastatic solid tumors; hepatocellular carcinoma (HCC); small cell lung cancer (SCLC); DLBCL

Sonrotoclax (BCL-2)

- BCL-2⁵ inhibitor with potential best-in-class properties
- A key molecule in hematology portfolio, highly potent and highly selective
- Indications: MCL; CLL; SLL; multiple myeloma; acute myeloid leukemia (AML); myelodysplastic syndrome (MDS)

BGB-A445 (OX-40)

- Unique investigational OX-40 agonist antibody that does not block ligand binding
- Distinguished method of action versus other antibodies in clinical development
- Indications: advanced solid tumors; melanoma; renal cell cancer (RCC); urothelial carcinoma (UC)

BGB-15025 (HPK1)

- Potential first-in-class investigational HPK1⁶ inhibitor
- Positioned to combine with tislelizumab in PD-1 sensitive tumors
- Indications: advanced solid tumors

BGB-11673 (BTK-CDAC)

- An investigational BTK CDAC molecule
- Indications: B-cell malignancies

BGB-B167 (CEA-4-1BB)

- Investigational CEA-4-1BB bispecific antibody
- Indications: advanced solid tumors

BGB-24174 (SMAC mimetic)

- Investigational SMAC mimetic
- Indications: advanced solid tumors

BGB-A425 (TIM-3)

- Investigational TIM-3 inhibitor
- Indications: advanced solid tumors

BGB-10188 (PI3K)

- Investigational PI3K inhibitor
- Indications: B-cell lymphoid malignancies and solid tumors

BGB-23339 (TYK2)

- An investigational TYK2 inhibitor
- Indications: inflammation and immunology

¹ Bruton's tyrosine kinase; ² Programmed cell death protein 1; ³ Poly ADP-ribose polymerase

⁴ T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains;

⁵ B-cell lymphoma ⁶ Hematopoietic progenitor kinase 1

Message from the Office of the Chief Medical Officer (Hematology) of BeiGene

Dear Prospective Fellow,

Thank you for your interest in the BeiGene Hematology-Oncology Clinical Development Fellowship in partnership with the University of Pacific Fellowship in Industry Program (FIP). At BeiGene, we truly believe that cancer has no borders, and neither should we, which is why we are pursuing a broad and deep pipeline with the potential to address 80 percent of the world's cancers by cancer type. Our global post-doctoral PharmD fellowship program aligns with our purpose of advancing global health, and making the highest quality therapies accessible to billions more people around the world.

PharmD graduates have a unique combination of scientific and clinical training that facilitates success not only in clinical research, but across all functions in our organization. BeiGene's two-year Hematology-Oncology Clinical Development Fellowship will pair you with experienced mentors who will provide impactful cross-functional opportunities to hone your skills as a clinical scientist, fostering your success within drug development and the biopharmaceutical industry. We seek a passionate fellow to join our team who shares our core values of putting patients first through bold ingenuity, a collaborative spirit, and driving excellence.

Best regards,

Mehrdad Mobashar, MD
Chief Medical Officer, Hematology
BeiGene



Toay Foster-Ortiz, MAOM
Executive Director, Chief of Staff to CMO
of Hematology
BeiGene



BeiGene Fellowship | Hematology-Oncology Clinical Development

Brief Overview

This two-year Hematology-Oncology Clinical Development fellowship provides extensive exposure to clinical development activities and fosters an understanding of clinical research principles. The fellow will function as a Clinical Scientist and will support Medical Directors/senior-level Clinical Scientists on a diverse set of clinical development activities.

BeiGene has built an extensive array of novel in vitro, ex vivo and in vivo cancer models to help better select targets, and to screen and evaluate agents that may have significant potential (alone or in combination). By integrating elements of the human immune system, their cancer models enable them to evaluate potential drug candidates in conditions that mimic cancer at the time of treatment. This is especially significant when drug discovery depends on evaluating multiple combinations and regimens that target specific mutations while simultaneously immobilizing cancer cells' defenses. In the role of a Clinical Scientist, the fellow will gain a strong foundation in clinical oncology research.

Program Director



Sheel Patel, PharmD

Associate Director, Clinical Science
BeiGene



Charity Henrich, PharmD

Clinical Science Fellow
BeiGene

Activities

The fellow will function as a clinical scientist and will support medical directors/senior level clinical scientists on the following activities:

- Serve as a clinical science representative on cross-functional sub-teams (i.e. protocol execution, clinical, biomarkers, pharmacokinetics)
- Create, review and present clinical slides for internal (i.e. BeiGene) and external meetings (e.g. Investigator meetings, scientific congresses, advisory boards, site visits, site staff training)
- Develop understanding of Good Clinical Practice (GCP), International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), FDA, EMA, NICE and other relevant guidelines and regulations
- Draft abstracts, posters, manuscripts for scientific meetings
- Author and review of clinical documents (i.e. clinical trial protocols, clarifications and amendments, informed consents, investigator brochures, clinical study reports, investigational new drug submissions)
- Respond to inquiries from health authorities (e.g. FDA, EMA) and study site ethics committees
- Partner with the data management team to assist with the development of case report forms
- Serve as a primary point of contact for study inquiries
- Contribute to ongoing review of the integrity of clinical trial data
- Develop understanding of the entire clinical development process from Phase I-IV

**CANCER
HAS NO BORDERS
NEITHER
DO WE**
— BeiGene —

Perspective from BeiGene Fellowship Sponsor

Dear Prospective Fellow,

A strong foundation is the key to future success, and completion of a rigorous and respected Industry Fellowship program is a great first step on the path to a successful career in the biopharmaceutical industry.

My 3+ decades of experience working in both biotechnology as well as pharmaceutical companies ranging in size from 40 to over 20,000 employees has exposed me to a wide variety of company cultures, organizational structures, management styles, and assets such as small molecules, large molecules, and recombinant DNA technology. I can categorically state that BeiGene offers a premier opportunity to learn the principals of drug development in a systematic manner. With office locations across 5 continents, BeiGene's world class R&D divisions are developing 40 assets in clinical or commercial stages with an additional 60+ pre-clinical programs. This deep portfolio provides ample practice for fellows to assume responsibility for complex and critical deliverables. They will develop the confidence to create innovative solutions, while cultivating strong cross-functional collaborative skills.

BeiGene's Hematology-Oncology Clinical Development Fellowship program is now well established and ready to welcome our next round of fellows for 2025. Designed by former Industry Fellowship graduates, our drug development fellowship will provide hands-on execution of development activities along with exposure to the cross-functional teamwork and communication that drive high performing teams. Our 2025 program has been thoughtfully crafted to ensure that a superior level of training, education, and mentorship is provided for our fellows. We look forward to meeting you!

Best regards,



Radha Prathikanti
Executive Director, Clinical Sciences
BeiGene

Fellowship in Industry Program

Brief Overview

The University of the Pacific's Fellowship in Industry Program (FIP) was founded in 2017 with the goal of providing exceptional biopharmaceutical industry training for PharmD graduates. We strive to deepen domain specific technical skills while sharpening soft skills for all fellows. The fellows will spend 90 percent of their time at BeiGene. The balance of time will be spent on professional development activities at the University.

University of the Pacific's FIP is unique for several reasons. The program:

1. Integrates pharmaceutical industry training with a blend of academia or hospital practice experiences.
2. Enhances research capabilities via engagement in the Innovative Clinical and Outcomes Research (iCOR) program.
3. Embraces the innovative culture of the San Francisco Bay Area, home to many health care startup companies.

Learn more at pacific.edu/pharmacy/icor

Program Mentors



Sachin A. Shah, PharmD, FACC, FAHA

Professor of Pharmacy Practice
Regional Coordinator – Travis
Director, Fellowship in Industry Program



Jeremy Lim, PharmD

Associate Director, Fellowship in Industry Program
Thomas J. Long School of Pharmacy

Activities at the Thomas J. Long School of Pharmacy

The fellow will have clinical faculty status at University of the Pacific, Thomas J. Long School of Pharmacy. They will be engaged in:

- Conducting research in collaboration with faculty
- Attending professional development meetings
- Developing grant and manuscript writing skills
- Advising Pacific's Industry Pharmacists Organization (IPhO) student chapter
- Mentoring rotational students in professional development and industry opportunities
- Participating in teaching activities (e.g. industry elective, research elective)

Program Mentors



Allen Shek, PharmD

Professor of Pharmacy Practice
Associate Dean of Professional Programs



**Kate M. O'Dell, PharmD,
BCPS, FCSHP**

Professor of Pharmacy Practice



**Nancy N. Nguyen, PharmD,
BCPS, AAHIVP, FCSHP**

Clinical Professor of Pharmacy Practice
Regional Coordinator – Palo Alto



**Sachin A. Shah, PharmD,
FACC, FAHA**

Professor of Pharmacy Practice
Regional Coordinator – Travis
Director, Fellowship in Industry Program



Select Publications from Former FIP fellows:

Posters and Publications

- **Oh E**, Owen R, Poon V, Wong K, Yoshida K. PKPD Modeling to Characterize Placebo and Treatment Effect of Omalizumab for Chronic Spontaneous Urticaria (CSU). Abstract at American Conference on Pharmacometrics (ACOP) Annual Meeting 2022; Aurora, CO, 2022.
- Dayal P, **Dimond C**, Yang X, Kent M, Rizzo S, Mohan D. Defining the Frequent Exacerbator Phenotype During a Pandemic in COPD. Abstract at American College of Chest Physicians (CHEST) Annual Meeting 2021; Orlando, FL 2021.
- **Dimond C**, Shah S, Dovan K, Tran B, Hsu K, Pham K, O'Dell K. Effects of Nelumbo nucifera extract on anxiety symptoms in individuals with moderate-to-severe anxiety.
- **Liu X, Kawakatsu S**, Tran B, Tran B, Manzeniero L, Shih E, Shek A, Lim J, Shah SA. Differences in Glucose Readings Between Right Arm and Left Arm Using a Continuous Glucose Monitor. Poster at American Heart Association-Scientific Sessions, 2020, Virtual Conference. (Abstract #13259). Published as a paper in Journal of Diabetes Science and Technology. <https://pubmed.ncbi.nlm.nih.gov/33955249/>
- **Kawakatsu S**, Zhu R, Zhang W, Tang MT, Lu T, Quartino A, Kågedal M. Longitudinal Placebo Response Modeling in Patients with Ulcerative Colitis. Poster at American Conference on Pharmacometrics; Aurora, CO, 2020.
- **Kawakatsu S**, Bruno R, Kågedal M, Li C, Girish S, Joshi A, Wu B. Confounding Factors in Exposure-Response Analyses and Mitigation Strategies for Monoclonal Antibodies in Oncology. <https://pubmed.ncbi.nlm.nih.gov/33217012/>
- Sathyamoorthya M, Verduzco-Gutierrez M, **Varanasi S**, et al. Enhanced external counterpulsation for management of symptoms associated with long COVID. American Heart Journal Plus: Cardiology Research and Practice. January 2022.
- Kunder R, Yeh F, Chinn L, Dash A, Lewin-Koh N, **Kim N**, Fredrickson J, Yoshida K, Chen S, Wilson M, and Wong C. Multiple Doses of an Anti-FGFR1/KLB Bispecific Antibody (BFKB8488A) are Associated with a Decrease in Hepatic Fat in Patients with NAFLD. Poster at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2019; Boston, MA 2019.
- **Kim N**, Pham K, Shek A, Lim J, **Liu X**, Shah SA. Differences in Glucose Level Between Right Arm and Left Arm Using Continuous Glucose Monitors. Published in Digital Health. <https://pubmed.ncbi.nlm.nih.gov/33224517/>

On-Going Clinical Research

- Time In Range Difference between Arms using Continuous Glucose Monitors in Patients with Diabetes. PIs: **Allen Lat**, PharmD, Sarika Mujumdar, PharmD
- Effects of a natural caffeinated energy drink on blood glucose parameters. PI: **Elise Oh**, PharmD.

UNIVERSITY OF THE
PACIFIC

Thomas J. Long
School of Pharmacy

